{
    "symbol": "ALVO",
    "quarter": 2,
    "year": 2022,
    "date": "2022-09-01 14:16:09",
    "content": " Since then, we have had substantial advancements across our portfolio, including IP clearance around totally product AVT02, a high concentration biosimilar to Hukyndra, as well as FDA acceptance of our BLA included supporting data to gain interchangeability for the US market. Having the high concentration products in addition to creating a potentially better patient experience with less volume on injection allows you to offer specific offerings only available in that strength, which can lower doses forces indications having interchangeability could potentially allow switching between an approved biosimilar and well over 80% of the US market."
}